肠道菌群与乙型肝炎肝硬化  

Gut microbiota in hepatitis B cirrhosis

作　　者：李艳男 李长政 LI Yannan;LI Changzheng(Department of Gastroenterology,Training Base for Postgraduate Students,PLA Rocket Force Characteristic Medical Center of Jinzhou Medical University,Beijing 100088,China;Department of Gastroenterology,PLA Rocket Force Characteristic Medical Center,Beijing 100088,China)

机构地区：[1]锦州医科大学火箭军特色医学中心研究生培养基地消化科,北京100088 [2]中国人民解放军火箭军特色医学中心消化科,北京100088

出　　处：《临床肝胆病杂志》2025年第3期552-555,共4页Journal of Clinical Hepatology

基　　金：中国人民解放军火箭军特色医学中心自主科研项目(25FC003)。

摘　　要：乙型肝炎肝硬化是我国肝硬化最主要组成部分,由肝炎发展到肝硬化后患者病死率明显增加。大量研究证实肠道菌群会影响乙型肝炎肝硬化病程进展,包括对炎症反应和肠道免疫调节的影响、对HBV的抑制、产生氨类物质等。本文就乙型肝炎肝硬化肠道菌群变化的研究进展进行综述,归纳通过干预肠道菌群治疗乙型肝炎肝硬化的新思路。Hepatitis B cirrhosis is the most significant component of liver cirrhosis in China,and there is a significant increase in the mortality rate of patients after progression from hepatitis to liver cirrhosis.A large number of studies have shown that gut microbiota may influence the progression of hepatitis B cirrhosis,including the impact on the regulation of inflammatory response and intestinal immunity,the inhibition of HBV,and the production of ammonia-like substances.This article reviews the research advances in the changes in gut microbiota in hepatitis B cirrhosis patients and explores new ideas for the treatment of hepatitis B cirrhosis by intervening in gut microbiota.

关 键 词：乙型肝炎 肝硬化 胃肠道微生物组 RNA 核糖体 16S 

分 类 号：R57[医药卫生—消化系统]